Compare · ABT vs REPH
ABT vs REPH
Side-by-side comparison of Abbott Laboratories (ABT) and Recro Pharma Inc. (REPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and REPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 2909.3x REPH ($69.1M).
- ABT has hit the wire 8 times in the past 4 weeks while REPH has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 1 for REPH).
- Company
- Abbott Laboratories
- Recro Pharma Inc.
- Price
- -
- -
- Market cap
- $200.95B
- $69.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Recro Pharma Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest REPH
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)
- Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)
- Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 34,096 shares, decreasing direct ownership by 4% to 729,007 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,419 shares, decreasing direct ownership by 0.19% to 763,103 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 5,690 shares, decreasing direct ownership by 0.74% to 764,522 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,197 shares, decreasing direct ownership by 0.16% to 770,212 units (SEC Form 4)
- Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits